Open access · OA
via OpenAlex
DNA Methylation and Environmental Exposures in Human Hepatocellular Carcinoma
JNCI Journal of the National Cancer Institute · 2002 · ▲ 246 citations
Abstract
BACKGROUND: Hypermethylation of a CpG-rich promoter (CpG island) blocks expression of the corresponding gene. The CpG island methylator phenotype (CIMP), defined as a variable pattern of hypermethylation of CpG islands in tumor suppressor genes, may be associated with carcinogenesis. To determine whether CIMP is associated with the development of hepatocellular carcinoma (HCC) and with exposure to environmental agents, we examined the methylation status of CpG islands in HCCs from countries with various HCC risks. METHODS: We examined the methylation status of 12 CpG islands (eight for known genes) in 85 HCC tumors from various geographic locations by use of bisulfite-polymerase chain reaction methylation assays and analyzed results with univariate and multivariable methods. All statistical tests were two-sided. RESULTS: Eight CpG islands were hypermethylated. The frequency of hypermethylation in the 85 tumors was 62% for the estrogen receptor (ER), 42% for p16, 18% for cyclooxygenase-2, 21% for the T-type calcium channel gene, 38% for MINT31, 28% for MINT1, 15% for MINT27, and 11% for MINT2 (the latter four CpG islands are not yet associated with genes). Methylation levels of the eight frequently methylated CpG islands were positively correlated (from R =.2 [P =.05] to R =.6 [P<.001]), supporting the presence of CIMP. p16 methylation had statistically significant geographic variation (34.4% in tumors from China and Egypt versus 12.2% in tumors from the United States and Europe, difference = 22.2%; 95% confidence interval [CI] = 11.2% to 33.2%; P<.001). Similar geographic variations were observed for ER methylation and CIMP. This observation was partly related to higher methylation in tumors from patients with cirrhosis (33.6% for patients with cirrhosis versus 11.7% for those without it; difference = 21.9%; 95% CI = 10.9% to 32.8%; P<.001) or hepatitis (34.2% for patients with hepatitis versus 6.2% for those without it; difference = 28%; 95% CI = 18.3% to 37.6%; P<.001). CONCLUSION: Geographic variations in the methylation status of various CpG islands indicate that environmental factors may influence the frequent and concordant degree of hypermethylation in multiple genes in HCC tumors.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1093/jnci/94.10.755
- Canonical
- link ↗
- Fetched
- 2026-06-09 MST
Cite this
APA
Shen, L. (2002). DNA Methylation and Environmental Exposures in Human Hepatocellular Carcinoma. <em>JNCI Journal of the National Cancer Institute</em>. https://doi.org/10.1093/jnci/94.10.755
Vancouver
Shen L. DNA Methylation and Environmental Exposures in Human Hepatocellular Carcinoma. JNCI Journal of the National Cancer Institute. 2002. doi:10.1093/jnci/94.10.755.
BibTeX
@article{lanlan2002DNAMet,
title = {DNA Methylation and Environmental Exposures in Human Hepatocellular Carcinoma},
author = {Lanlan Shen},
journal = {JNCI Journal of the National Cancer Institute},
year = {2002},
doi = {10.1093/jnci/94.10.755},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
American Journal Of Pathology 2002
Open access · OA
Epstein-Barr Virus-Positive Gastric Carcinoma Demonstrates Frequent Aberrant Methylation of Multiple Genes and Constitutes CpG Island Methylator Phenotype-Positive Gastric Carcinoma
Oncology Reports 2006
Open access · OA
Promoter methylation status of the MGMT, hMLH1, and CDKN2A/p16 genes in non-neoplastic mucosa of patients with and without colorectal adenomas
Electrophoresis 2000
Citation only
The role of DNA hypermethylation in human neoplasia
Aging Cell 2022
Open access · CC-BY
DNA methylation signatures in Blood DNA of Hutchinson–Gilford Progeria syndrome
Nature Communications 2014
Open access · CC-BY
Dynamic DNA methylation orchestrates cardiomyocyte development, maturation and disease
Cancer Research 2006
Preprint · OA